A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
Public ClinicalTrials.gov record NCT01305746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Long-term Safety Extension Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
Study identification
- NCT ID
- NCT01305746
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 382 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2011 (Type not available)
- Primary completion
- Jul 2013 (Actual)
- Completion
- Oct 2013 (Actual)
- Last update posted
- Feb 13, 2014
2011 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 103 | Birmingham | Alabama | 35294 | — |
| Investigator Site 113 | Long Beach | California | 90806 | — |
| Investigator Site 110 | Upland | California | 91786 | — |
| Investigator Site 105 | Orlando | Florida | 32806 | — |
| Investigator Site 102 | Tampa | Florida | 33614 | — |
| Investigator Site 117 | Baltimore | Maryland | 21205 | — |
| Investigator Site 104 | Lansing | Michigan | 48910 | — |
| Investigator Site 106 | Lake Success | New York | 11042 | — |
| Investigator Site 114 | Smithtown | New York | 11787 | — |
| Investigator Site 101 | Greenville | North Carolina | 27834 | — |
| Investigator Site 112 | Oklahoma City | Oklahoma | 73104 | — |
| Investigator Site 111 | Tulsa | Oklahoma | 74104 | — |
| Investigator Site 115 | Houston | Texas | 77034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01305746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2014 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01305746 live on ClinicalTrials.gov.